Cargando…
LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials)
BACKGROUND: To determine the effectiveness and safety of LCZ696 for the clinical treatment of hypertension, we performed a meta-analysis of the previous clinical trials. METHODS: Relevant English articles and randomized controlled trials were searched in Pubmed, Embase, EBSCO, Cochrane base and Clin...
Autores principales: | Ye, Liwen, Wang, Jian, Chen, Qingwei, Yang, Xixi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746120/ https://www.ncbi.nlm.nih.gov/pubmed/29296218 http://dx.doi.org/10.18632/oncotarget.22442 |
Ejemplares similares
-
A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension
por: Zheng, Li, et al.
Publicado: (2021) -
The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Chua, Su-Kiat, et al.
Publicado: (2021) -
LCZ696 ameliorates lipopolysaccharide-induced endothelial injury
por: Gao, Aihong, et al.
Publicado: (2021) -
Effect and safety of LCZ696 in the treatment of hypertension: A meta-analysis of 9 RCT studies
por: Li, Qiongqiong, et al.
Publicado: (2019) -
Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
por: Li, Bo, et al.
Publicado: (2017)